Nothing Special   »   [go: up one dir, main page]

CN114981272A - 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 - Google Patents

吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 Download PDF

Info

Publication number
CN114981272A
CN114981272A CN202180008532.8A CN202180008532A CN114981272A CN 114981272 A CN114981272 A CN 114981272A CN 202180008532 A CN202180008532 A CN 202180008532A CN 114981272 A CN114981272 A CN 114981272A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008532.8A
Other languages
English (en)
Inventor
梁洪铭
张喜全
王训强
于鼎
王栋
葛琪
王昭
王旖旎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN114981272A publication Critical patent/CN114981272A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

吡咯并嘧啶化合物治疗噬血细胞综合征的用途,具体涉及式(I)化合物、其立体异构体、或其药学上可接受的盐及其药物组合物治疗噬血细胞综合征的用途。

Description

PCT国内申请,说明书已公开。

Claims (15)

  1. PCT国内申请,权利要求书已公开。
CN202180008532.8A 2020-03-09 2021-03-09 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 Pending CN114981272A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010157375 2020-03-09
CN2020101573754 2020-03-09
PCT/CN2021/079820 WO2021180093A1 (zh) 2020-03-09 2021-03-09 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途

Publications (1)

Publication Number Publication Date
CN114981272A true CN114981272A (zh) 2022-08-30

Family

ID=77670447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008532.8A Pending CN114981272A (zh) 2020-03-09 2021-03-09 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途

Country Status (4)

Country Link
US (1) US20230133735A1 (zh)
EP (1) EP4119562A4 (zh)
CN (1) CN114981272A (zh)
WO (1) WO2021180093A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3904356A4 (en) * 2018-12-24 2022-09-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND
AU2022296552A1 (en) * 2021-06-21 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease
WO2023179547A1 (zh) * 2022-03-21 2023-09-28 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024027790A1 (zh) * 2022-08-04 2024-02-08 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗急性移植物抗宿主病的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101777A1 (zh) * 2015-12-15 2017-06-22 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物的盐
WO2017114461A1 (zh) * 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 一种芦可替尼的合成工艺
CN107001378A (zh) * 2014-12-16 2017-08-01 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物
WO2017215628A1 (zh) * 2016-06-16 2017-12-21 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
WO2017215630A1 (zh) * 2016-06-16 2017-12-21 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
WO2017215627A1 (zh) * 2016-06-16 2017-12-21 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001378A (zh) * 2014-12-16 2017-08-01 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物
WO2017101777A1 (zh) * 2015-12-15 2017-06-22 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物的盐
WO2017114461A1 (zh) * 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 一种芦可替尼的合成工艺
WO2017215628A1 (zh) * 2016-06-16 2017-12-21 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
WO2017215630A1 (zh) * 2016-06-16 2017-12-21 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
WO2017215627A1 (zh) * 2016-06-16 2017-12-21 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASRA AHMED,等: "Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial", 《THE LANCET HAEMATOLOGY》, vol. 6, no. 12, 16 September 2019 (2019-09-16), pages 630 *
RAMANAN KESAVAN MELARCODE,等: "Successful remission induction in refractory familial hemophagocytic lymphohistiocytosiswith ruxolitinib as a bridge to hematopoietic stem cell transplantation", 《PEDIATRIC BLOOD AND CANCER》, vol. 67, no. 3, 25 November 2019 (2019-11-25), pages 1 - 2 *
SCOTT R. GOLDSMITH,等: "Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib", 《BLOOD ADVANCES》, vol. 3, no. 23, 10 December 2019 (2019-12-10), pages 4131 - 4135, XP093137772, DOI: 10.1182/bloodadvances.2019000898 *
SOPHIA MASCHALIDI,等: "Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice", 《BLOOD》, vol. 128, no. 1, 24 May 2016 (2016-05-24), pages 60 - 71, XP055577022, DOI: 10.1182/blood-2016-02-700013 *
王晶石,等: "芦可替尼挽救治疗难治/复发噬血细胞综合征三例并文献复习", 《中华血液学杂志》, vol. 40, no. 1, pages 73 - 75 *

Also Published As

Publication number Publication date
WO2021180093A1 (zh) 2021-09-16
EP4119562A4 (en) 2024-04-24
EP4119562A1 (en) 2023-01-18
US20230133735A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CN114981272A (zh) 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途
CN110833544B (zh) 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
JPS61176523A (ja) 制癌剤
US11299480B2 (en) 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors
AU2017231832B2 (en) CXCR-2 inhibitors for treating crystal arthropathy disorders
JP4153564B2 (ja) 薬物性腎障害または薬物性肝障害の予防及び治療組成物
JP2016517843A (ja) 新規なStat3阻害剤
WO2021179959A1 (zh) 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
TW202131926A (zh) 包含alk2抑制劑及jak2抑制劑的組合療法
WO2021207598A1 (en) Combination treatment with an agonist of p53 and a second therapeutic agent
WO2022268083A1 (zh) 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途
US20090275614A1 (en) Methylphenidate Derivatives and Uses of Them
CN118973582A (zh) 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
JP4585186B2 (ja) 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
WO2023179547A1 (zh) 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024088392A1 (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途
JP2946377B2 (ja) TNF−α及びIL−6産生抑制剤
JP2002537224A (ja) NF−κB活性化阻害剤及びそれらの医薬としての使用
WO2023011415A1 (zh) Egfr抑制剂的药物组合及其应用
CN115252620A (zh) 一种喹唑啉化合物及药物组合物的应用
JPH07324035A (ja) 滑膜細胞増殖抑制剤及び慢性関節リウマチ治療剤
CN118490680A (zh) 瑞香素在制备治疗病毒性肺炎的药物中的应用
CN118593502A (zh) 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用
TW202432141A (zh) 治療骨髓增生性腫瘤的方法
WO2024027790A1 (zh) 吡咯并嘧啶化合物治疗急性移植物抗宿主病的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination